Technology | December 22, 2014

AliveCor Launches Third Generation Heart Monitor Smartphone App System

New compact medical grade mobile ECG device is 50-percent thinner, 40-percent lighter

AliveCor Heart Monitor, third generation, ECG, atrial fibrillation, AF

December 22, 2014 — AliveCor Inc. announced the launch of its third-generation AliveCor Heart Monitor. Now users have the ability to identify and manage heart conditions with a U.S. Food and Drug Administration (FDA)-cleared electrocardiogram (ECG) monitor, anywhere and at anytime. The third-generation device is now 50-percent thinner and 40-percent lighter and was designed from first-hand customer feedback and in collaboration with global design firm IDEO.

Atrial fibrillation (AF) continues to be the most common heart rhythm disturbance, affecting more than 140 million people worldwide. AliveCor is focused on helping those with diagnosed and undiagnosed heart conditions, by providing patients and caregivers a tool to detect and manage heart conditions.

Users of the AliveCor Heart Monitor are recording 130,000 ECGs per month and actively tracking over 10,000 symptoms, medications and activities that may be affecting their health. In the two months since the AF Detector algorithm was launched, AliveCor has detected more than 20,000 incidents of AF in more than 30 percent of users recording ECGs.

Detecting AF is the first step to initiating a treatment plan to reduce stroke risk, as people with AF are five times more likely to suffer a stroke than those without the condition. Additionally, users continue to engage with the product over time: 70 percent are regularly using the device after six months.

“I used to get frustrated when I would experience what I thought was an AF episode but couldn’t get to the doctor’s office fast enough to confirm my instincts,” said Terry Reilly, AliveCor patient since 2012. “With the AliveCor Heart Monitor, I am relieved to have an easy-to-use tool at my fingertips that can instantly detect my AF episodes when they happen.”

“The AliveCor Heart Monitor leads to results that I can use to manage my patients remotely, a trend that is here to stay," said Jeffrey Olgin, M.D., chief, division of cardiology co-director, Heart and Vascular Center at the University of California San Francisco. “Seeing my patients’ ECG results in real-time is the next best thing to having them in my office when the event takes place.” 

“Big data and personalized medicine are revolutionizing the delivery of care and have the potential to disrupt the way we think about healthcare. We are excited to be on the forefront of helping patients manage their cardiac health,” said Euan Thomson, president and chief executive officer at AliveCor. “The newest generation of the Heart Monitor confirms AliveCor’s ongoing commitment to help stop the unnecessary loss of life and healthcare costs driven by undiagnosed and under-managed heart arrhythmias that lead to potentially life-threatening conditions like strokes.”

For more information: www.alivecor.com


Related Content

News | Atrial Fibrillation

Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to ...

Home November 19, 2024
Home
News | Atrial Fibrillation

Oct. 18, 2024 — The Heart Rhythm Society (HRS) Board of Trustees unanimously approved the formation of Heart Rhythm ...

Home October 21, 2024
Home
News | Atrial Fibrillation

Sept. 11, 2024 — In the first national estimate in two decades, researchers at the University of California-San ...

Home September 11, 2024
Home
News | Atrial Fibrillation

July 24, 2024 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist ...

Home July 24, 2024
Home
News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
Subscribe Now